Acorda Therapeutics delays start of Phase 3 study of dalfampridine-QD to 2H Acorda Therapeutics announced that the initiation of its Phase 3 study of dalfampridine-QD in people with post-stroke walking deficits will begin in the second half of 2014; previously the company had projected study initiation in the second quarter of 2014. The developer of the once-daily, or QD, formulation has informed the company of an alcohol dose dumping finding in vitro and the company will need to perform a short clinical study to determine whether this also exists in vivo. The clinical study will be conducted in healthy volunteers and is expected to be completed in the third quarter of 2014, Acorda said.
News For ACOR From The Last 14 Days
Check below for free stories on ACOR the last two weeks.